| Title |
Switching statin-treated patients from fenofibrate to the prescription omega-3 therapy icosapent ethyl: a retrospective case series
|
|---|---|
| Published in |
Drugs & Therapy Perspectives, March 2016
|
| DOI | 10.1007/s40267-016-0288-3 |
| Pubmed ID | |
| Authors |
Richard S. Castaldo |
| Abstract |
Patients receiving statin therapy for dyslipidaemia often require treatment with an additional agent to control triglyceride levels. Options for add-on therapy include fibrates and omega-3 fatty acids. This case series describes the effects of switching add-on therapy from fenofibrate to icosapent ethyl (the ethyl ester of the omega-3 fatty acid, eicosapentaenoic acid) on patient lipid profiles. This was a retrospective analysis of patient records from a private medical practice in western New York. Statin-treated patients with dyslipidaemia who had been treated with fenofibrate and later switched to icosapent ethyl were selected for analysis. Lipid profiles before and after the switch to icosapent ethyl were compared. The records of five patients were analysed. All patients had hypertension and were overweight, male, and at high cardiovascular risk. After the switch to icosapent ethyl (treatment duration 3.9-5.8 months), triglyceride levels decreased in four patients, and low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and total cholesterol levels decreased in all patients. High-density lipoprotein levels increased in four patients. Icosapent ethyl was well tolerated. Switching from fenofibrate to icosapent ethyl as add-on to a statin therapy due to clinical need may provide an option for patients to maintain or improve lipid parameters. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 3 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 6% |
| Unknown | 15 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Unspecified | 2 | 13% |
| Student > Master | 2 | 13% |
| Researcher | 2 | 13% |
| Student > Ph. D. Student | 2 | 13% |
| Other | 1 | 6% |
| Other | 3 | 19% |
| Unknown | 4 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 3 | 19% |
| Unspecified | 2 | 13% |
| Agricultural and Biological Sciences | 2 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 6% |
| Nursing and Health Professions | 1 | 6% |
| Other | 0 | 0% |
| Unknown | 7 | 44% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 April 2019.
All research outputs
#13,462,624
of 22,856,968 outputs
Outputs from Drugs & Therapy Perspectives
#70
of 206 outputs
Outputs of similar age
#144,421
of 299,380 outputs
Outputs of similar age from Drugs & Therapy Perspectives
#2
of 4 outputs
Altmetric has tracked 22,856,968 research outputs across all sources so far. This one is in the 39th percentile – i.e., 39% of other outputs scored the same or lower than it.
So far Altmetric has tracked 206 research outputs from this source. They receive a mean Attention Score of 3.2. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 299,380 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.